3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
2
Dermatologic
2
Other hematologic neoplasm
1
Lymphoid
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
CNS
1
Breast
1
Conditions
Carcinoma, Renal Cell
4
Neoplasm Metastasis
3
Melanoma
3
Urinary Bladder Neoplasms
2
Triple Negative Breast Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Transitional Cell
2
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma
1
Recurrence
1
Metastatic Castration-resistant Prostate Cancer
1
Kidney Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
Interventions
Peripheral Blood Stem Cell Transplantation
6
Cyclophosphamide
6
fludarabine phosphate
5
Nivolumab
5
Mycophenolic Acid
5
Carboplatin
5
Whole-Body Irradiation
4
Radiotherapy
4
Filgrastim
4
Cyclosporine
4
Gemcitabine
3
Cisplatin
3
Busulfan
3
Antilymphocyte Serum
3
cabozantinib
2
cabazitaxel
2
Voriconazole
2
Thiotepa
2
Therapeutics
2
Standard of Care
2
Sirolimus
2
Polymerase Chain Reaction
2
Mitomycin
2
Methylprednisolone
2
Methotrexate
2
Melphalan
2
Itraconazole
2
Immunoglobulin G
2
Goserelin
2
Flow Cytometry
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recurrence
×
bempegaldesleukin
×
Genitourinary
×
Clear all
NCT03435640
2023-03-08
REVEAL
Nektar Therapeutics
Phase 1/2
Terminated
64 enrolled
22 charts